Next Article in Journal
Exploring the Therapeutic Potential of Membrane Transport Proteins: Focus on Cancer and Chemoresistance
Next Article in Special Issue
Advances in Anti-Cancer Immunotherapy: Car-T Cell, Checkpoint Inhibitors, Dendritic Cell Vaccines, and Oncolytic Viruses, and Emerging Cellular and Molecular Targets
Previous Article in Journal
Cellular Plasticity and Tumor Microenvironment in Gliomas: The Struggle to Hit a Moving Target
Previous Article in Special Issue
Development of a VLP-Based Vaccine Displaying an xCT Extracellular Domain for the Treatment of Metastatic Breast Cancer
Article

HLA Class I Allele Expression and Clinical Outcome in De Novo Metastatic Prostate Cancer

1
Cancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital, 171 Alexandras avenue, 11522 Athens, Greece
2
Department of Urology, Saint Savas Cancer Hospital, 171 Alexandras avenue, 11522 Athens, Greece
*
Author to whom correspondence should be addressed.
These authors contributed equally to this paper.
Cancers 2020, 12(6), 1623; https://doi.org/10.3390/cancers12061623
Received: 21 May 2020 / Revised: 9 June 2020 / Accepted: 11 June 2020 / Published: 18 June 2020
The prognostic value of human leukocyte antigen (HLA) class I molecules in prostate cancer (PCa) remains unclear. Herein, we investigated the prognostic relevance of the most frequently expressed HLA-A alleles in Greece (A*02:01 and HLA-A*24:02) in de novo metastatic hormone-sensitive PCa (mPCa), which is a rare and aggressive disease characterized by a rapid progression to castration-resistance (CR) and poor overall survival (OS), contributing to almost 50% of PCa-related deaths. We identified 56 patients who had either progressed to CR (these patients were retrospectively analyzed for the time to the progression of CR and prospectively for OS) or had at least three months’ follow-up postdiagnosis without CR progression and, thus, were prospectively analyzed for both CR and OS. Patients expressing HLA-A*02:01 showed poor clinical outcomes vs. HLA-A*02:01negative patients. HLA-A*24:02positive patients progressed slower to CR and had increased OS. Homozygous HLA-A*02:01 patients progressed severely to CR, with very short OS. Multivariate analyses ascribed to both HLA alleles significant prognostic values for the time to progression (TTP) to CR and OS. The presence of HLA-A*02:01 and HLA-A*24:02 alleles in de novo mPCa patients are significantly and independently associated with unfavorable or favorable clinical outcomes, respectively, suggesting their possible prognostic relevance for treatment decision-making in the context of precision medicine. View Full-Text
Keywords: HLA-alleles; HLA-A*02:01; HLA-A*24:02; prognosis; de novo metastatic prostate cancer HLA-alleles; HLA-A*02:01; HLA-A*24:02; prognosis; de novo metastatic prostate cancer
Show Figures

Figure 1

MDPI and ACS Style

Stokidis, S.; Fortis, S.P.; Kogionou, P.; Anagnostou, T.; Perez, S.A.; Baxevanis, C.N. HLA Class I Allele Expression and Clinical Outcome in De Novo Metastatic Prostate Cancer. Cancers 2020, 12, 1623. https://doi.org/10.3390/cancers12061623

AMA Style

Stokidis S, Fortis SP, Kogionou P, Anagnostou T, Perez SA, Baxevanis CN. HLA Class I Allele Expression and Clinical Outcome in De Novo Metastatic Prostate Cancer. Cancers. 2020; 12(6):1623. https://doi.org/10.3390/cancers12061623

Chicago/Turabian Style

Stokidis, Savvas, Sotirios P. Fortis, Paraskevi Kogionou, Theodoros Anagnostou, Sonia A. Perez, and Constantin N. Baxevanis 2020. "HLA Class I Allele Expression and Clinical Outcome in De Novo Metastatic Prostate Cancer" Cancers 12, no. 6: 1623. https://doi.org/10.3390/cancers12061623

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop